Evaluate Pharma-Yearbook

Company Performance Tables

Publication Date July 2008
ISBN n/a
Pages 130
Tables n/a
Figures n/a

Print £1500 $2355

 Add to Basket

PDF £1450 $2275

Single user

 Add to Basket
Essential reading for everybody in the pharmaceutical market from senior executives and corporate strategists

In a fast-changing pharmaceutical market it is vital to be able to measure company performance easily and accurately.

Find out which companies are winning in the areas that count and which are suffering in changing circumstances. The new Evaluate Pharma-Yearbook gives you the information that you need, in context.

The Yearbook provides information and data of the highest quality, taken directly from the EvaluatePharma? database and it will enable you to:

  • Benchmark company revenue and expenditure
  • Analyse company performance
  • Assess mergers and acquisitions
  • Understand patent expiry issues
  • Match R&D spend to performance
  • Analyse sales by therapy area, licensing, acquisitions etc
  • Analyse winners and losers by therapy area
All of the detailed information in the Yearbook is put in context by explanations of the new pharmaceutical market place, how it works and how companies perform within it.

The Yearbook provides detailed information about the top 150 companies, including:

  • Revenue
  • Income
  • Growth
  • R&D expenditure
  • M&A activity
  • Patent expiry
  • Staffing levels
  • Expenditure
It is essential reading for everybody in the pharmaceutical market from senior executives and corporate strategists, through marketing and sales departments to market analysts and pharmaceutical outsourcing companies.
Executive Summary

Chapter 1. Company performance
The performance of the world's top 150 companies, ranked on 2007 prescription (Rx) and OTC sales, analysed by revenue, profit, market cap, net cash, employee numbers, selling and general expenses and cost of goods.

Chapter 2. Performance analysis
Detailed analysis of the 150 top companies - ranking their PE ratios and growth in Rx & OTC sales, normalised net income and market cap within three groups: Rx & OTC sales of more than $10 billion; $1-$10 billion; and less than $1 billion.

Chapter 3. Operational efficiency
Company expenditure on R&D, SG&A (selling, general and administration) and CoGs (cost of goods sold), and all three as a proportion of sales, are compared within sector peer groups.

Chapter 4. Shifting sands
Global sales in 12 therapeutic areas as a proportion of sales from 2000-2007 shows the highest growth areas are in constant flux. The ten winners and losers in each category are picked out to convey how companies are positioning themselves to best exploit these movements.

Chapter 5. Strategic thinking
Global sales by technology shows that biotech sales are growing at the expense of
conventional chemical sales. Global sales by strategy shows that organic R&D has been losing out to acquired R&D. And an analysis of the industry's sales that are US patentprotected for at least five years has never been lower.

Chapter 6. Market developments
One response to the $8.3 billion losses expected from US patent expiries in 2007 and the falling number of US approvals has been to accelerate the number of licensing deals.

Appendices

Notes

List of Tables

Chapter 1: Company performance, 2006-2007
1.1: Total Rx & OTC sales
1.2: Net income
1.3: Normalised net income
1.4: Market capitalisation
1.5: Price-earnings ratio
1.6: Cash in the bank

Chapter 2. Performance analysis
2.1.1: Growth rankings for total Rx & OTC sales: companies earning > $10 billion
2.1.2: Growth rankings for normalised net income: companies earning > $10 billion
2.1.3: Growth rankings for market cap and share price: companies earning > $10 billion
2.1.4: Rankings of price-earnings ratios: companies earning > $10 billion
2.1.5: Mergers and acquisitions: companies earning > $10 billion

2.2.1: Growth rankings for total Rx & OTC sales: companies earning $1 billion - $10 billion
2.2.2: Growth rankings for normalised net income: companies earning $1 billion - $10 billion
2.2.3: Growth rankings for market cap and share price: companies earning $1 billion - $10 billion
2.2.4: Rankings of price-earnings ratios: companies earning $1 billion - $10 billion
2.2.5: Mergers and acquisitions: companies earning $1 billion - $10 billion

2.3.1: Growth rankings for total Rx & OTC sales: companies earning < $10 billion
2.3.2: Growth rankings for normalised net income: companies earning < $10billion
2.3.3: Growth rankings for market cap and share price: companies earning < $10billion
2.3.4: Rankings of price-earnings ratios: companies earning < $10billion
2.3.5: Mergers and acquisitions: companies earning < $10 billion

Chapter 3. Operational efficiency
3.1 Employee numbers
3.2 R&D spend and as a proportion of sales, by business sector
3.3 SG&A spend and as a proportion of sales, by business sector
3.4 CoGs spend and as a proportion of sales, by business sector

Chapter 4. Shifting sands
4.1: US sales growth, 2000-2007 & US sales as a % of pharma sales for the global majors, 2000-2007
4.2: Pharma sales by therapeutic area, 2000-2007
4.2.1: Therapeutic sales as a % of Rx & OTC sales for global majors, 2000-2007
4.3: Generics company sales, 2006-2007
4.4: Speciality company sales, 2006-2007

Chapter 5. Strategic thinking
5.1: Worldwide sales by technology, 2000-2007
5.1.1: Sales by technolgy for global majors, 2000-2007
5.2: Worldwide sales by strategy, 2000-2007
5.2.1: Sales by strategy for global majors, 2000-2007
5.3: Worldwide sales by patent risk, 2000-2007
5.3.1: Sales by patent risk for global majors, 2000-2007

Chapter 6. Market developments
6.1: FDA approvals and research products abandoned, 2003-2007
6.2: US patent expiries of products with US sales of more than $100 million (2007-2011) showing US annual sales, 2007-2012
6.3: Major licensing deals in 2007

Appendix 1
 Total pharmaceutica sales (2007) showing sales from Rx, OTC, total Rx & OTC, alliance/co-promotion, royalty & licensing and other pharma (including bulk sales)

Appendix 2.1
Top companies by market capitalisation

Appendix 2.2
Top companies by sector

Appendix 2.3
Top companies by country

Appendix 3
Company profiles

EvaluatePharma offers unique insight into the pharmaceutical and biotechnology industry.

EvaluatePharma is staffed by a team of dedicated Healthcare Analysts with degrees in Life Sciences or Economics, MBAs and Chartered Accountancy qualifications. The team employs a rigorous and consistent methodology to collate, organize and deliver the most-up-to-date commercial data via the EvaluatePharma service.